Cachet Pharmaceutical (SHE:002462) said China's State Administration for Market Regulation has approved Beijing Tongrentang's (SHA:600085) acquisition of a 28.48% stake in the company, clearing the anti-monopoly review.
Upon completion, Tongrentang Group will become Cachet Pharmaceutical's controlling shareholder, according to a Tuesday filing with the Shenzhen bourse.
The deal involves the transfer of 83.1 million shares from China Everbright Medical and Everbright Industrial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments